Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 3, 2001, Pages 177-187

  Koch, C J ^a   Hahn, S M ^a   Rockwell, K ^a   Covey, J ^a   McKenna, W ^a   Evans, S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hypoxia detection; Plasma half life; Predictive assays; Radiation sensitizers; Renal clearance

Indexed keywords

2 (2 NITRO 1 H IMIDAZOL 1 YL) N (2,2,3,3,3, PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; 2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; ETANIDAZOLE; METRONIDAZOLE; MISONIDAZOLE; NIMORAZOLE; NORMISONIDAZOLE; PIMONIDAZOLE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COVALENT BOND; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CLEARANCE; MALE; OXYGEN TISSUE LEVEL; PARTITION COEFFICIENT; PHASE 1 CLINICAL TRIAL; PLASMA HALF LIFE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANOXIA; AREA UNDER CURVE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETANIDAZOLE; HALF-LIFE; HUMANS; HYDROCARBONS, FLUORINATED; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIATION-SENSITIZING AGENTS; SEX FACTORS; TISSUE DISTRIBUTION;

EID: 0034879404     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100324     Document Type: Article

References (59)

1. Selective activation of drugs by redox processes
2. Electron-affinic sensitization VII. A correlation between structure, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers
3. SR-2508: A 2-nitroimidazole amide which should be superior tomisonidazole as a radiosensitizer for clinical use
4. Depletion of tumor oxygenation during photodynamic therapy: Detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl) acetamide]
5. Radiation-induced events and their time scale in mammalian cells
6. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells
7. Adduct formation by 2-nitroimidazole drugs in mammalian cells: Optimization of markers for tissue oxygenation
8. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
9. Retention of misonidazole in normal and malignant tissues: Interplay of hypoxia and reductases
10. Initial pharmacology and toxicology of intravenous desmethylmisonidazole
11. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508
12. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile
13. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): A Radiation Therapy Oncology Group study
14. Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses
15. Neurotoxicity with desmethylmisonidazole
16. [18]F-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure
17. 2-Nitroimidazole (EF5) binding predicts radiation sensitivity in individual 9L subcutaneous tumors
18. Non-invasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1
19. Detection of hypoxia in human squamous cell carcinoma by EF5 binding
20. Hypoxia in human intraperitoneal and extremity sarcomas
21. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: Some preliminary results
22. The labelling of EMT-6 tumors in Balb/c mice with 14C-misonidazole
23. Clinical testing of the radiosensitizer Ro-07-0582. I. Dose tolerance, serum and tumour concentrations
24. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection
25. Hypoxia and necrosis in rat (L glioma and Morris 7777 hepatoma tumors: Comparative measurements using EF5 binding and Eppendoff needle electrode
26. Synthesis and in vivo studies of the radiosensitizer 4-(82Br)bromomisonidazole
27. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays
28. The reductive activation of nitroimidazoles: Modification by oxygen and other redox-active molecules in cellular systems
29. Metabolism induced binding of14C-misonidazole to hypoxic cells: Kinetic dependence on oxygen concentration and misonidazole concentration
30. Combined radiation-protective and radiation-sensitizing agents: III) Radiosensitization by misonidazole as a function of concentrations of endogenous glutathione or exogenous thiols
31. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoroproply) acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity
32. Biodistribution of the nitroimidazole EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in mice bearing subcutaneous EMT6 tumors
33. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts
34. Electrophilic intermediate in the reactions of a 2-(hydroxylamino)imidazole. A model for biological effects of reduced nitroimidazoles
35. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
36. Studies of the pharmacokinetic properties of Nimorazole
37. The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules
38. Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumours in Balb/c mice: Detection by F-19 nuclear magnetic resonance at 2.35 T
39. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours
40. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia
41. A phase I study of etanidazole and radiotherapy in malignant glioma
42. A clinical phase I toxicity study of Ro 03-8799; plasma, urine, tumor and normal brain pharmacokinetics
43. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: A preliminary study
44. Clinical testing of Ro 03-8799 pharmacokinetics, toxicology, tissue and tumor concentrations
45. I.V. misonidazole (NSC261037). Report of initial clinical experience
46. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy
47. Desmethylmisonidazole (Ro 05-9963): Clinical pharmacokinetics after multiple oral administration
48. A toxicity study of daily dose metronidazole with pelvic irradiation
49. A phase I clinical study of nimorazole as a hypoxic radiosensitizer
50. Phase I study of high-dose metronidazole: A specific in vivo and in vitro radiosensitizer of hypoxic cells
51. Peripheral neuropathy related to misonidazole incidence and pathology
52. Clinical trials with hypoxic cell sensitizers: Time to retrench or time to push forward?
53. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole
54. The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799
55. Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues
56. Pharmacokinetics of hypoxic cell radiosensitizers
57. The experimental development of bioreductive drugs and their role in cancer therapy
58. Enzyme directed bioreductive drug development